Inspire Pharmaceuticals Q2 Revenue Increases By 5%

Inspire Pharmaceuticals has posted a net loss of $9.5m or $0.17 per share for the second quarter which ended on June 30, 2009, compared to a net loss of $6.4m, or $0.11 per common share, for the same period prior year. Total revenue for the second quarter of 2009 was $23.10m, compared to $22.0m for the same period previous year, reflecting an increase of 5%.

Total revenue for the six months ended June 30, 2009 was $37.4m and represented an 18% increase over the total revenue of $31.7m for the same period in 2008. Total revenue for the six months ended June 30, 2009 was comprised of $23.6m of co-promotion and royalty revenue on net sales of Restasis and Elestat and $13.8m of AzaSite revenue, as compared to $24.1m and $6.4m, respectively, recognized for the six months ended June 30, 2008.